Prognostic value of peripheral blood and bone marrow infiltration assessed by flow cytometry in dogs with de novo nodal peripheral T-cell lymphoma receiving alkylating-rich chemotherapy

Marconato, L.; Comazzi, S.; Agnoli, C.; Aresu, L.; Stefanello, D.; Riondato, F.; Gamberini, L.; Sabattini, S.

doi:10.1016/j.tvjl.2023.106057

Cited by 3 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dogs with aggressive and indolent B-cell lymphoma received a CHOP-based chemotherapeutic protocol 31 with or without an autologous vaccine 5 , based on the clinician's and owner's preferences. 32,33 , two alkylating-rich protocols with similar clinical activities, based on the clinician's and owner's preferences. Dogs with indolent T-cell lymphoma were treated with oral chlorambucil and prednisolone if indicated by the tumor load and/or the presence of clinical signs (substage b).…”

Section: Animal Recruitment and Sample Acquisitionmentioning

confidence: 99%

The K9 lymphoma assay allows a genetic subgrouping of canine lymphomas with improved risk classification

Aresu,

Fanelli,

Licenziato

et al. 2024

Preprint

View full text Add to dashboard Cite

We developed a targeted next-generation sequencing approach designed for the genomic classification of canine lymphoma. Positioned within the evolving landscape of comparative and veterinary oncology, this study underscores the clinical significance of tailored genetic profiling for this tumor in dogs, marking a crucial step in diagnostic high-throughput genetic analysis. Leveraging a previous dataset, the “K9 lymphoma assay” demonstrated robust comparability and reproducibility in canine diffuse large B-cell lymphoma (DLBCL), when matched with previously tumors examined through whole-exome sequencing. Expanding our investigation to encompass several B- and T-cell lymphoma histotypes, we unveiled distinct mutational landscapes distinguishing nodal lymphomas derived from immature lymphocytes and nodal lymphomas originating from mature lymphocytes. TRAF3 was the most frequently altered gene in B-cell lymphomas, exhibiting unique mutational patterns. Key genetic events, such as TP53 and SETD2 mutations, clinically demonstrated universal implications across B-cell lymphomas, positioning them as potential prognostic and therapeutic indicators. These findings advocate for a tailored therapeutic approach directly impacting treatment decisions and outcomes in managing canine lymphomas. Our study provides the largest and most comprehensive genomic characterization of clinically staged canine lymphomas to date, and it provides pivotal insights for future research and therapeutic strategies in comparative oncology.

show abstract

Section: Animal Recruitment and Sample Acquisitionmentioning

confidence: 99%

The K9 lymphoma assay allows a genetic subgrouping of canine lymphomas with improved risk classification

Aresu,

Fanelli,

Licenziato

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

The K9 lymphoma assay allows a genetic subgrouping of canine lymphomas with improved risk classification

Fanelli,

Licenziato,

Mazzone

et al. 2024

Sci Rep

View full text Add to dashboard Cite

We present here the K9 lymphoma assay, a novel 31-gene targeted next-generation sequencing panel designed for genomic profiling of canine lymphoid neoplasms. Addressing the growing demand for advanced diagnostics in veterinary oncology, this assay enables sensitive identification of known and actionable mutations specific to canine lymphomas, while evaluating its prognostic potential to facilitate diagnosis and prognosis. Our analysis, spanning several B- and T-cell lymphoma histotypes, unveiled distinct mutational landscapes distinguishing tumors derived from immature versus mature lymphocytes. Clustering analysis revealed a shared genetic origin between diffuse large B-cell lymphoma and marginal zone lymphoma, aligning with findings in human lymphomas, with TRAF3 emerging as the most frequently mutated gene across B-cell lymphoma subtypes. Significantly, TP53 mutations demonstrated universal adverse prognostic implications across B-cell lymphomas. Additionally, SETD2 mutations contributed to shorter time-to-progression, underscoring the role of epigenetic dysregulation in B-cell tumors. In T-cell lymphomas, SATB1 and FBXW7 were frequently mutated, warranting further investigation in larger cohorts. Our findings advocate for tailored therapeutic approaches based on the genetic profile, impacting treatment decisions and outcomes in canine lymphoma management. This study provides pivotal insights bridging veterinary and human oncology, paving the way for comprehensive genomic diagnostics and therapeutic strategies in comparative oncology.

show abstract

Large granular lymphocyte lymphoma in 65 dogs (2005–2023)

Yale,

Crawford,

Gramer

et al. 2023

Vet Comparative Oncology

View full text Add to dashboard Cite

Large granular lymphocyte lymphoma (LGLL) is a rare form of lymphoma in dogs. Limited information exists regarding presentation, treatment response, and outcome. The aim of this single‐institute, retrospective study was to characterise clinical presentation, biologic behaviour, outcomes, and prognostic factors for dogs with LGLL. Cytologic review was also performed. Sixty‐five dogs were included. The most common breed was the Labrador retriever (29.2%), and the most common presenting signs were lethargy (60.0%) and hyporexia (55.4%). The most common primary anatomic forms were hepatosplenic (32.8%) and gastrointestinal (20.7%). Twenty dogs (30.8%) had peripheral blood or bone marrow involvement. Thirty‐two dogs were treated with maximum tolerated dose chemotherapy (MTDC) with a response documented in 74.1% of dogs. Dogs ≥7 years, and those with neutropenia or thrombocytopenia at diagnosis had the reduced likelihood of response to treatment. For dogs treated with MTDC median progression‐free interval (PFI) was 17 days (range, 0–481), the median overall survival time (OST) 28 days (range, 3–421), and the 6‐month and 1‐year survival rates were 9.4% and 3.1%, respectively. On multivariable analysis, monocytosis and peripheral blood involvement were significantly associated with shorter PFI and OST. Long‐term survival (≥100 days) was significantly associated with intermediate lymphocyte size on cytology. Dogs with LGLL have moderate response rates to chemotherapy but poor overall survival. Additional studies are needed to further evaluate prognostic factors and guide optimum treatment recommendations.

show abstract

Prognostic value of peripheral blood and bone marrow infiltration assessed by flow cytometry in dogs with de novo nodal peripheral T-cell lymphoma receiving alkylating-rich chemotherapy

Cited by 3 publications

References 26 publications

The K9 lymphoma assay allows a genetic subgrouping of canine lymphomas with improved risk classification

The K9 lymphoma assay allows a genetic subgrouping of canine lymphomas with improved risk classification

The K9 lymphoma assay allows a genetic subgrouping of canine lymphomas with improved risk classification

Large granular lymphocyte lymphoma in 65 dogs (2005–2023)

Contact Info

Product

Resources

About